NCT03168438View on ClinicalTrials.gov

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 18, 2017

Primary Completion Date

July 13, 2020

Study Completion Date

November 5, 2020

Conditions
Neoplasms
Interventions
DRUG

Letetresgene autoleucel

Letetresgene autoleucel (GSK3377794) as an IV infusion

DRUG

Letetresgene autoleucel with pembrolizumab

Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks

DRUG

Fludarabine

Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.

DRUG

Cyclophosphamide

Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

DRUG

Pembrolizumab

Pembrolizumab is available as an IV infusion

Trial Locations (5)

21201

GSK Investigational Site, Baltimore

30322

GSK Investigational Site, Atlanta

33136

GSK Investigational Site, Miami

91010

GSK Investigational Site, Duarte

33612-9497

GSK Investigational Site, Tampa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY